Dullens H F, Schakenraad S, Oostdijk A, Vuist W, Van der Maas M, Den Otter W
Cancer Immunol Immunother. 1986;22(2):100-6. doi: 10.1007/BF00199122.
The antitumor potency and specificity of syngeneic immune peritoneal exudate cells were tested. Groups of DBA/2 mice were immunized against syngeneic SL2 tumor cells. Then 6 days after the last immunization the antitumor potency, and the specificity of the immunization reaction was tested by injecting groups of the immunized mice with 10(3) to 5 X 10(7) DBA/2 derived L1210, L5178Y, P815 or SL2 tumor cells, and injecting immune peritoneal exudate cells into DBA/2 mice which had been injected 2 h earlier i.p. with 2 X 10(4) or 2 X 10(5) L1210, L5178Y, P815, or SL2 cells. Furthermore the tumor specific cytotoxicity in vitro of isolated immune (vs SL2) peritoneal macrophages was tested against L1210, L5178Y, P815, and SL2 cells. The "reciprocal" experiments (previous immunization against L1210, L5178Y, or P815 cells and 'challenge' with SL2) were also done. Finally, we tested the tumor-specific cytotoxicity of isolated immune peritoneal T-lymphocytes. It was shown that the rejection of tumor cells in previously immunized mice, the antitumor efficacy of the transferred immune peritoneal exudate cells and the in vitro cytotoxicity of purified immune peritoneal macrophages and lymphocytes, were tumor-specific reactions. That is only between the SL2 and L5178Y tumors were cross-reactions observed. However, this cross-reaction was not found at the level of cytotoxic T-cells. This suggests that cytotoxic T-cells and cytotoxic macrophages probably have different mechanisms of recognition of the specific tumor target cells. Treatment of macrophage monolayers, prepared from macrophages of immunized mice, with monoclonal anti-Thy-1 antibodies plus complement caused no decrease in cytotoxicity. This shows that macrophages can really express specific cytotoxicity. Tumoricidal macrophages probably obtain their tumor specificity through the activities of tumor-specific factors produced by sensitized T-cells.
对同基因免疫腹膜渗出细胞的抗肿瘤效力和特异性进行了测试。将DBA/2小鼠分组,用同基因SL2肿瘤细胞进行免疫。在最后一次免疫后6天,通过给免疫小鼠组注射10³至5×10⁷个源自DBA/2的L1210、L5178Y、P815或SL2肿瘤细胞,并将免疫腹膜渗出细胞注射到2小时前腹腔注射了2×10⁴或2×10⁵个L1210、L5178Y、P815或SL2细胞的DBA/2小鼠中,来测试抗肿瘤效力和免疫反应的特异性。此外,还测试了分离的免疫(针对SL2)腹膜巨噬细胞对L1210、L5178Y、P815和SL2细胞的体外肿瘤特异性细胞毒性。还进行了“反向”实验(先前针对L1210、L5178Y或P815细胞进行免疫,并用SL2“攻击”)。最后,我们测试了分离的免疫腹膜T淋巴细胞的肿瘤特异性细胞毒性。结果表明,先前免疫小鼠中肿瘤细胞的排斥、转移的免疫腹膜渗出细胞的抗肿瘤功效以及纯化的免疫腹膜巨噬细胞和淋巴细胞的体外细胞毒性,均为肿瘤特异性反应。也就是说,仅在SL2和L5178Y肿瘤之间观察到交叉反应。然而,在细胞毒性T细胞水平未发现这种交叉反应。这表明细胞毒性T细胞和细胞毒性巨噬细胞可能具有不同的识别特定肿瘤靶细胞的机制。用单克隆抗Thy-1抗体加补体处理由免疫小鼠的巨噬细胞制备的巨噬细胞单层,细胞毒性没有降低。这表明巨噬细胞确实可以表达特异性细胞毒性。杀肿瘤巨噬细胞可能通过致敏T细胞产生的肿瘤特异性因子的活性获得其肿瘤特异性。